title: Medication Effects on EEG Biomarkers in Attention-Deficit/Hyperactivity Disorder.
abstract: EEG biomarkers have become increasingly used to aid in diagnosis of attention-deficit/hyperactivity disorder (ADHD). Despite several studies suggesting that EEG theta/beta ratio may help discriminating ADHD from other disorders, the effect of medications on theta/beta ratio is not known. Forty-three children with ADHD that were evaluated with quantitative EEG before and after methylphenidate were included in the study. Theta/beta ratio, theta and beta powers for whole brain, central, and frontal areas were calculated. Theta/beta power decreased significantly after treatment; however, this change was largely due to an increase in beta power, rather than a fall in theta power. The results suggest that beta power is sensitive to medication effects, while theta power remains as a trait biomarker unaffected by medication status. The value of EEG biomarkers for monitoring neuropsychological performance and clinical status should be explored by future studies.
authors: 1 Department of Child and Adolescent Psychiatry, NPIstanbul Neuropsychiatry Hospital, Istanbul, Turkey.|2 Department of Psychology, Uskudar University, Istanbul, Turkey.
authors: Havva Nuket
authors: HN
authors: Isiten
authors: 2 Department of Psychology, Uskudar University, Istanbul, Turkey.
authors: Merve
authors: M
authors: Cebi
authors: 2 Department of Psychology, Uskudar University, Istanbul, Turkey.
authors: Bernis
authors: B
authors: Sutcubasi Kaya
authors: 2 Department of Psychology, Uskudar University, Istanbul, Turkey.
authors: Baris
authors: B
authors: Metin
authors: 2 Department of Psychology, Uskudar University, Istanbul, Turkey.|3 Department of Psychiatry, NPIstanbul Neuropsychiatry Hospital, Istanbul, Turkey.
authors: Nevzat
authors: N
authors: Tarhan
mesh_terms: D000293:Adolescent; D000928:Antidepressive Agents / Q000008:administration & dosage; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D015415:Biomarkers; D058256:Brain Waves / Q000187:drug effects*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D002648:Child; D003913:Dextroamphetamine / Q000008:administration & dosage; D018492:Dopamine Antagonists / Q000008:administration & dosage; D016903:Drug Monitoring; D004569:Electroencephalography / Q000187:drug effects* / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000008:administration & dosage; D015588:Observer Variation; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D015415:Biomarkers; D000697:Central Nervous System Stimulants; D018492:Dopamine Antagonists; D008774:Methylphenidate; D003913:Dextroamphetamine
keywords: EEG biomarker; attention-deficit/hyperactivity disorder; methylphenidate; relative power; theta/beta ratio